ID: ALA4438132

Max Phase: Preclinical

Molecular Formula: C29H31N3O6S

Molecular Weight: 549.65

Molecule Type: Unknown

Representations

Canonical SMILES:  COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ccccc2)nc1OCCO

Standard InChI:  InChI=1S/C29H31N3O6S/c1-29(2,3)21-14-16-22(17-15-21)39(34,35)32-27-25(38-24-13-9-8-12-23(24)36-4)28(37-19-18-33)31-26(30-27)20-10-6-5-7-11-20/h5-17,33H,18-19H2,1-4H3,(H,30,31,32)

Standard InChI Key:  HVRDENHNEUGHGW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 549.65

Molecular Weight (Monoisotopic): 549.1934

AlogP: 5.41

#Rotatable Bonds: 10

Polar Surface Area: 119.87

Molecular Species: ACID

HBA: 8

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 5.82

CX Basic pKa: 3.35

CX LogP: 6.17

CX LogD: 5.21

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.27

Np Likeness Score: -0.97

References

1. Boss C, Bolli MH, Gatfield J..  (2016)  From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.,  26  (15): [PMID:27321813] [10.1016/j.bmcl.2016.06.014]

2. Zheng W, Wang Z, Jiang X, Zhao Q, Shen J..  (2020)  Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.,  63  (24.0): [PMID:33314936] [10.1021/acs.jmedchem.0c01093]

Source

Source(1):

• Scientific Literature